Target：p35

Fields：Alzheimer disease;Pathways of neurodegeneration - multiple diseases;Cocaine addiction

Gene Name：CDK5R1

Protein Name：Cyclin-dependent kinase 5 activator 1

Human Gene Id：8851

Human Swiss Prot No：Q15078

Mouse Gene Id：12569

Mouse Swiss Prot No：P61809

Rat Gene Id：116671

Rat Swiss Prot No：P61810

Immunogen：The antiserum was produced against synthesized peptide derived from human CDK5R1. AA range:11-60

Specificity：p35 Polyclonal Antibody detects endogenous levels of p35 protein.

Formulation：Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Source：Polyclonal, Rabbit,IgG

Dilution：WB 1:500 - 1:2000. IHC 1:100 - 1:300. IF 1:200 - 1:1000. ELISA: 1:20000. Not yet tested in other applications.

Purification：The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration：1 mg/ml

Storage Stability：-15°C to -25°C/1 year(Do not lower than -25°C)

Other Name：CDK5R1;CDK5R;NCK5A;Cyclin-dependent kinase 5 activator 1;CDK5 activator 1;Cyclin-dependent kinase 5 regulatory subunit 1;TPKII regulatory subunit

Observed Band(KD)：38kD

Background： The protein encoded by this gene (p35) is a neuron-specific activator of cyclin-dependent kinase 5 (CDK5); the activation of CDK5 is required for proper development of the central nervous system. The p35 form of this protein is proteolytically cleaved by calpain, generating a p25 form. The cleavage of p35 into p25 results in relocalization of the protein from the cell periphery to nuclear and perinuclear regions. P25 deregulates CDK5 activity by prolonging its activation and changing its cellular location. The p25 form accumulates in the brain neurons of patients with Alzheimer's disease. This accumulation correlates with an increase in CDK5 kinase activity, and may lead to aberrantly phosphorylated forms of the microtubule-associated protein tau, which contributes to Alzheimer's disease. [provided by RefSeq, Jul 2008],

Function：disease:Cleavage of p35 to p25 may be involved in the pathogenesis of Alzheimer disease. The p25 form accumulates in neurons in the brain of patients with Alzheimer disease, but not in normal brain. This accumulation correlates with an increase in CDK5 kinase activity. Application of amyloid beta peptide A-beta(1-42) induced the conversion of p35 to p25 in primary cortical neurons. Expression of the p25/Cdk5 complex in cultured primary neurons induces cytoskeletal disruption, morphological degeneration and apoptosis.,function:p35 is a neuron specific activator of CDK5. The complex p35/CDK5 is required for neurite outgrowth and cortical lamination. Activator of TPKII.,PTM:Probably myristoylated. The Gly-2-Ala mutant is absent of the cell periphery, suggesting that a proper myristoylation signal is essential for the proper distribution of p35.,PTM:The p35 form is proteolytically cleaved by

Subcellular Location：[Cyclin-dependent kinase 5 activator 1, p35]: Cell membrane ; Lipid-anchor ; Cytoplasmic side . Cell projection, neuron projection . In the primary cortical neurons, p35 is present in the peripheries and nerve terminals. .; [Cyclin-dependent kinase 5 activator 1, p25]: Nucleus . Cytoplasm, perinuclear region . Perikaryon . The conversion of p35 to p25 relocalizes the protein from the cell periphery to the cytoplasm, in nuclear and perinuclear regions (PubMed:18507738). In the primary cortical neurons, p25 is primarily concentrated in the cell soma and is largely absent from neurites (PubMed:18507738). .

Expression：Brain and neuron specific.